Genocea Biosciences, a vaccine discovery and development company based in Cambridge, Mass., this week announced that it has hired George Siber as executive chairman.
Siber was previously the executive vice president and chief scientific officer of Wyeth Vaccines. Prior to joining Wyeth, Siber was director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School associate professor of medicine at Dana Farber Cancer Institute.
In recognition of his contributions to this field, the recently completed $100 million Massachusetts Biologic Laboratory building for vaccine development and manufacturing was dedicated to Siber and his colleague Jeanne Leszczynski.
The Automation Partnership this week announced that it has recruited Kim Bure, Steve Deal, and Linda Jesse as new associate directors of its US commercial group. The new staff will strengthen TAP’s US presence and offer direct, rapid contact with TAP’s technical expertise.
Bure, who has a degree in chemistry from Northwestern University, has 14 years of experience with two major US life science equipment and consumables suppliers, and contract research organizations.
Deal has seven years of experience with a leading drug discovery automation firm, and has an additional 13 years experience marketing life science equipment and consumables.
Jesse has 20 years of experience marketing life science consumables specializing in cell culture products, gained by working for three major suppliers in this field. Jesse will also provide support with automated cell culture applications.